Monday, August 31, 2026

Moderna Stock Is 4.97% Down So Far On Tuesday

ViaNews Editorial Team

December 1, 2020

Moderna Stock Is 4.97% Down So Far On Tuesday

Shares of Moderna fell 4.97% to $145.15 at 14:11 EST on Tuesday, after three consecutive sessions in a row of gains. The Nasdaq Stock Market is rising 1.47% to $12,377.60, following yesterday's downward trend, on what up until now seems, an all-around positive trend exchanging session today.

Moderna's last close was $152.74, 22.98% under its 52-week high of $178.50.

News about Moderna today

Moderna mania draws bitcoin comparisons while shorts bleed. According to today's article on Bloomberg Quint, "Moderna Mania Draws Comparisons to Bitcoin While Shorts Bleed."

Moderna's Sales

Moderna's sales growth is 1425.2% for the ongoing quarter and 9666.5% for the next. The company's growth estimates for the present quarter is a negative 48.6% and positive 528.6% for the next.

Moderna's Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's Stock Top and Bottom Yearly Value

Moderna's stock is valued at $145.15 at 14:11 EST, way below its 52-week high of $178.50 and way above its 52-week low of $17.68.

Moderna's Moving Average

Moderna's worth is way above its 50-day moving average of $82.84 and way higher than its 200-day moving average of $71.63.

Previous days news about Moderna

Moderna set to file for us, EU clearance for its coronavirus vaccine. According to yesterday's article on ForexLive, "Moderna reaffirms that its vaccine is 94.1% effective in primary analysis - Vaccine was 94.1% effective in analysis of Phase 3 study, after 196 virus cases - Vaccine was 100% effective against strict virus cases in trial Another Monday, another dose of vaccine optimism to hit the market."

Moderna to ask FDA to authorize vaccine. According to yesterday's article on The Wall Street Journal, "Moderna will ask U.S"

According to yesterday's article on Bloomberg Quint, "Moderna Plans to Seek U.S., EU Clearance for Covid Vaccine."

Moderna to file EUA for coronavirus vaccine candidate, which previewed 94.1% efficacy. According to yesterday's article on MarketWatch, "Moderna Inc"

According to yesterday's article on MarketWatch, "Moderna shares soar 11% on filing for emergency-use authorization for vaccine."

Stocks making the biggest moves premarket: Moderna, IHS markit, slack & more. According to yesterday's article on CNBC, "Some of the stocks posting the largest moves before the bell include Moderna, IHS Markit, Slack, and more.."

Stocks making the biggest moves premarket: Moderna, IHS markit, slack & more. According to yesterday's article on CNBC, "Some of the stocks posting the largest moves before the bell include Moderna, IHS Markit, Slack, and more.."

Stocks making the biggest moves midday: Moderna, IHS markit, nikola, Carnival & more. According to yesterday's article on CNBC, "Moderna shares rereport on strong efficacy data."

Stocks making the biggest moves midday: Moderna, IHS markit, nikola, Carnival & more. According to yesterday's article on CNBC, "Moderna shares rereport on strong efficacy data."

According to yesterday's article on Bloomberg Quint, "Moderna Seeks Approval; WHO Spotlights Risks: Virus Update."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com